HC Wainwright Issues Negative Forecast for Biodesix Earnings

Key Points

• HC Wainwright cut its FY2026 EPS forecast for Biodesix to a loss of $3.13 per share from $2.72, below the analyst consensus estimate of a $2.81 loss, while keeping its Buy rating and $34 price target.
• Biodesix’s latest quarterly loss of $0.75 per share matched consensus, but revenue of $24.04 million fell short of analysts’ $27.48 million expectation.
• Analyst sentiment remains broadly positive: MarketBeat reports a Moderate Buy consensus and a $34.20 average price target, though recent target changes have varied.

Biodesix, Inc. (NASDAQ:BDSX - Free Report) - HC Wainwright dropped their FY2026 earnings per share (EPS) estimates for Biodesix in a note issued to investors on Monday, November 9th. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings of ($3.13) per share for the year, down from their prior forecast of ($2.72). HC Wainwright has a "Buy" rating and a $34.00 price objective on the stock. The consensus estimate for Biodesix's current full-year earnings is ($2.81) per share. HC Wainwright also issued estimates for Biodesix's Q4 2026 earnings at ($0.86) EPS, Q1 2027 earnings at ($0.75) EPS, Q2 2027 earnings at ($0.56) EPS, Q3 2027 earnings at ($0.50) EPS, Q4 2027 earnings at ($0.40) EPS and FY2027 earnings at ($2.18) EPS.

Other analysts have also issued research reports about the stock. Lake Street Capital cut their target price on shares of Biodesix from $40.00 to $30.00 and set a "buy" rating on the stock in a research report on Friday, November 6th. Weiss Ratings upgraded shares of Biodesix from a "sell (e+)" rating to a "sell (d-)" rating in a report on Tuesday, September 8th. Canaccord Genuity Group raised their price objective on Biodesix from $27.00 to $35.00 and gave the company a "buy" rating in a report on Monday, August 10th. Finally, TD Cowen reissued a "buy" rating and set a $40.00 price objective (up from $30.00) on shares of Biodesix in a report on Tuesday, October 13th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $34.20.

Biodesix Trading Down 3.1%

Shares of Biodesix stock opened at $10.02 on Wednesday. The firm's 50 day moving average is $24.87 and its 200 day moving average is $18.89. The firm has a market capitalization of $111.12 million, a PE ratio of -3.63 and a beta of 0.65. Biodesix has a 1 year low of $5.26 and a 1 year high of $31.97. The company has a current ratio of 2.85, a quick ratio of 2.85 and a debt-to-equity ratio of 5.12.

Biodesix (NASDAQ:BDSX - Get Free Report) last posted its earnings results on Thursday, November 5th. The company reported ($0.75) EPS for the quarter, hitting analysts' consensus estimates of ($0.75). Biodesix had a negative net margin of 25.74% and a negative return on equity of 513.78%. The firm had revenue of $24.04 million during the quarter, compared to analysts' expectations of $27.48 million.

Institutional Investors Weigh In On Biodesix

A number of institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. bought a new position in shares of Biodesix during the second quarter valued at $970,000. Sei Investments Co. bought a new stake in shares of Biodesix in the first quarter worth $624,000. GSA Capital Partners LLP bought a new stake in shares of Biodesix in the second quarter worth $1,060,000. Walleye Capital LLC bought a new stake in shares of Biodesix in the second quarter worth $1,679,000. Finally, Stempoint Capital LP acquired a new stake in Biodesix in the first quarter valued at $1,015,000. 20.96% of the stock is owned by institutional investors.

Biodesix Company Profile

Biodesix, Inc. is a data-driven diagnostic solutions company focused on improving the diagnosis and treatment of lung diseases, including lung cancer. The company combines proprietary molecular diagnostic technologies, clinical data, and artificial intelligence to help physicians assess disease risk and make more informed treatment decisions. Its offerings include blood-based tests designed to help evaluate indeterminate pulmonary nodules, identify patients who may be at higher risk of lung cancer, and support treatment selection and monitoring.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.